Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease

Margaret McCusker, Nicole Basset-Seguin, Reinhard Dummer, Karl Lewis, Dirk Schadendorf, Aleksandar D Sekulic, Jeannie Hou, Lisa Wang, Huibin Yue, Axel Hauschild

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Purpose This review provides a description of the epidemiology and survival outcomes for cases with metastatic basal cell carcinoma (mBCC) based on published reports (1981-2011). Methods A literature search (MEDLINE via PubMed) was conducted for mBCC case reports published in English: 1981-2011. There were 172 cases that met the following criteria: primary BCC located on skin, metastasis confirmed by pathology and metastasis not resulting from direct tumour spread. From these, 100 mBCC cases with explicit information on follow-up time were selected for analysis. Survival analysis was conducted using Kaplan-Meier methods. Results Among 100 mBCC cases selected for analysis, including one case with Gorlin syndrome, 50% had regional metastases (RM) and 50% had distant metastases (DM). Cases with DM were younger at mBCC diagnosis (mean age, 58.0 versus 66.3 years for RM; P = 0.0013). Among 93 (of 100) cases with treatment information for metastatic disease, more DM cases received chemotherapy (36.2% versus 6.5% for RM), but more RM cases underwent surgery (87.0% versus 40.4% for DM). Among all 100 cases, median survival after mBCC diagnosis was 54 months (95% confidence interval (CI), 24-72), with shorter survival in DM (24 months; 95% CI, 12-35) versus RM cases (87 months; 95% CI, 63-not evaluable). Conclusion Cases with RM and DM mBCC may have different clinical courses and outcomes. Based on published reports, DM cases were younger at mBCC diagnosis, with shorter median survival than RM cases. This study provides a historical context for emerging mBCC treatments.

Original languageEnglish (US)
Pages (from-to)774-783
Number of pages10
JournalEuropean Journal of Cancer
Volume50
Issue number4
DOIs
StatePublished - Mar 2014

Fingerprint

Basal Cell Carcinoma
Neoplasm Metastasis
Confidence Intervals
Basal Cell Nevus Syndrome
Survival Analysis
PubMed
MEDLINE

Keywords

  • Carcinoma, basal cell/secondary
  • Epidemiology
  • Neoplasm metastasis
  • Skin neoplasms/pathology
  • Treatment outcome

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

McCusker, M., Basset-Seguin, N., Dummer, R., Lewis, K., Schadendorf, D., Sekulic, A. D., ... Hauschild, A. (2014). Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease. European Journal of Cancer, 50(4), 774-783. https://doi.org/10.1016/j.ejca.2013.12.013

Metastatic basal cell carcinoma : Prognosis dependent on anatomic site and spread of disease. / McCusker, Margaret; Basset-Seguin, Nicole; Dummer, Reinhard; Lewis, Karl; Schadendorf, Dirk; Sekulic, Aleksandar D; Hou, Jeannie; Wang, Lisa; Yue, Huibin; Hauschild, Axel.

In: European Journal of Cancer, Vol. 50, No. 4, 03.2014, p. 774-783.

Research output: Contribution to journalArticle

McCusker, M, Basset-Seguin, N, Dummer, R, Lewis, K, Schadendorf, D, Sekulic, AD, Hou, J, Wang, L, Yue, H & Hauschild, A 2014, 'Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease', European Journal of Cancer, vol. 50, no. 4, pp. 774-783. https://doi.org/10.1016/j.ejca.2013.12.013
McCusker, Margaret ; Basset-Seguin, Nicole ; Dummer, Reinhard ; Lewis, Karl ; Schadendorf, Dirk ; Sekulic, Aleksandar D ; Hou, Jeannie ; Wang, Lisa ; Yue, Huibin ; Hauschild, Axel. / Metastatic basal cell carcinoma : Prognosis dependent on anatomic site and spread of disease. In: European Journal of Cancer. 2014 ; Vol. 50, No. 4. pp. 774-783.
@article{7e873b33da134c148d952092c4b69d27,
title = "Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease",
abstract = "Purpose This review provides a description of the epidemiology and survival outcomes for cases with metastatic basal cell carcinoma (mBCC) based on published reports (1981-2011). Methods A literature search (MEDLINE via PubMed) was conducted for mBCC case reports published in English: 1981-2011. There were 172 cases that met the following criteria: primary BCC located on skin, metastasis confirmed by pathology and metastasis not resulting from direct tumour spread. From these, 100 mBCC cases with explicit information on follow-up time were selected for analysis. Survival analysis was conducted using Kaplan-Meier methods. Results Among 100 mBCC cases selected for analysis, including one case with Gorlin syndrome, 50{\%} had regional metastases (RM) and 50{\%} had distant metastases (DM). Cases with DM were younger at mBCC diagnosis (mean age, 58.0 versus 66.3 years for RM; P = 0.0013). Among 93 (of 100) cases with treatment information for metastatic disease, more DM cases received chemotherapy (36.2{\%} versus 6.5{\%} for RM), but more RM cases underwent surgery (87.0{\%} versus 40.4{\%} for DM). Among all 100 cases, median survival after mBCC diagnosis was 54 months (95{\%} confidence interval (CI), 24-72), with shorter survival in DM (24 months; 95{\%} CI, 12-35) versus RM cases (87 months; 95{\%} CI, 63-not evaluable). Conclusion Cases with RM and DM mBCC may have different clinical courses and outcomes. Based on published reports, DM cases were younger at mBCC diagnosis, with shorter median survival than RM cases. This study provides a historical context for emerging mBCC treatments.",
keywords = "Carcinoma, basal cell/secondary, Epidemiology, Neoplasm metastasis, Skin neoplasms/pathology, Treatment outcome",
author = "Margaret McCusker and Nicole Basset-Seguin and Reinhard Dummer and Karl Lewis and Dirk Schadendorf and Sekulic, {Aleksandar D} and Jeannie Hou and Lisa Wang and Huibin Yue and Axel Hauschild",
year = "2014",
month = "3",
doi = "10.1016/j.ejca.2013.12.013",
language = "English (US)",
volume = "50",
pages = "774--783",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Metastatic basal cell carcinoma

T2 - Prognosis dependent on anatomic site and spread of disease

AU - McCusker, Margaret

AU - Basset-Seguin, Nicole

AU - Dummer, Reinhard

AU - Lewis, Karl

AU - Schadendorf, Dirk

AU - Sekulic, Aleksandar D

AU - Hou, Jeannie

AU - Wang, Lisa

AU - Yue, Huibin

AU - Hauschild, Axel

PY - 2014/3

Y1 - 2014/3

N2 - Purpose This review provides a description of the epidemiology and survival outcomes for cases with metastatic basal cell carcinoma (mBCC) based on published reports (1981-2011). Methods A literature search (MEDLINE via PubMed) was conducted for mBCC case reports published in English: 1981-2011. There were 172 cases that met the following criteria: primary BCC located on skin, metastasis confirmed by pathology and metastasis not resulting from direct tumour spread. From these, 100 mBCC cases with explicit information on follow-up time were selected for analysis. Survival analysis was conducted using Kaplan-Meier methods. Results Among 100 mBCC cases selected for analysis, including one case with Gorlin syndrome, 50% had regional metastases (RM) and 50% had distant metastases (DM). Cases with DM were younger at mBCC diagnosis (mean age, 58.0 versus 66.3 years for RM; P = 0.0013). Among 93 (of 100) cases with treatment information for metastatic disease, more DM cases received chemotherapy (36.2% versus 6.5% for RM), but more RM cases underwent surgery (87.0% versus 40.4% for DM). Among all 100 cases, median survival after mBCC diagnosis was 54 months (95% confidence interval (CI), 24-72), with shorter survival in DM (24 months; 95% CI, 12-35) versus RM cases (87 months; 95% CI, 63-not evaluable). Conclusion Cases with RM and DM mBCC may have different clinical courses and outcomes. Based on published reports, DM cases were younger at mBCC diagnosis, with shorter median survival than RM cases. This study provides a historical context for emerging mBCC treatments.

AB - Purpose This review provides a description of the epidemiology and survival outcomes for cases with metastatic basal cell carcinoma (mBCC) based on published reports (1981-2011). Methods A literature search (MEDLINE via PubMed) was conducted for mBCC case reports published in English: 1981-2011. There were 172 cases that met the following criteria: primary BCC located on skin, metastasis confirmed by pathology and metastasis not resulting from direct tumour spread. From these, 100 mBCC cases with explicit information on follow-up time were selected for analysis. Survival analysis was conducted using Kaplan-Meier methods. Results Among 100 mBCC cases selected for analysis, including one case with Gorlin syndrome, 50% had regional metastases (RM) and 50% had distant metastases (DM). Cases with DM were younger at mBCC diagnosis (mean age, 58.0 versus 66.3 years for RM; P = 0.0013). Among 93 (of 100) cases with treatment information for metastatic disease, more DM cases received chemotherapy (36.2% versus 6.5% for RM), but more RM cases underwent surgery (87.0% versus 40.4% for DM). Among all 100 cases, median survival after mBCC diagnosis was 54 months (95% confidence interval (CI), 24-72), with shorter survival in DM (24 months; 95% CI, 12-35) versus RM cases (87 months; 95% CI, 63-not evaluable). Conclusion Cases with RM and DM mBCC may have different clinical courses and outcomes. Based on published reports, DM cases were younger at mBCC diagnosis, with shorter median survival than RM cases. This study provides a historical context for emerging mBCC treatments.

KW - Carcinoma, basal cell/secondary

KW - Epidemiology

KW - Neoplasm metastasis

KW - Skin neoplasms/pathology

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=84894065660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894065660&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2013.12.013

DO - 10.1016/j.ejca.2013.12.013

M3 - Article

C2 - 24412051

AN - SCOPUS:84894065660

VL - 50

SP - 774

EP - 783

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4

ER -